Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sleiman, Sama F., Berlin, Jill, Basso, Manuela, S.Karuppagounder, Saravanan, Rohr, Jürgen, Ratan, Rajiv R.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349345/
https://ncbi.nlm.nih.gov/pubmed/22582024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph4081183
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky